• 1
    Yoshida A, Rzhetsky A, Hsu LC et al. Human aldehyde dehydrogenase gene family. Eur J Biochem 1998; 251: 549557.
  • 2
    Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem Biol Interact 2003; 143–144: 522.
  • 3
    Wang JS, Fang Q, Sun DJ et al. Genetic modification of hematopoietic progenitor cells for combined resistance to 4-hydroperoxycyclophosphamide, vincristine, and daunorubicin. Acta Pharmacol Sin 2001; 22: 949955.
  • 4
    Duester G. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem 2000; 267: 43154324.
  • 5
    Kastan MB, Schlaffer E, Russo JE et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 19471950.
  • 6
    Jones RJ, Barber JP, Vala MS et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85: 27422746.
  • 7
    Storms RW, Trujillo AP, Springer JB et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999; 96: 91189123.
  • 8
    Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996; 87: 47544761.
  • 9
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730737.
  • 10
    de Groot CJ, Martens AC, Hagenbeek A. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo. Eur J Cancer 1994; 30A: 21372143.
  • 11
    Russo JE, Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 1988; 48: 29632968.
  • 12
    Takebe N, Zhao SC, Adhikari D et al. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther 2001; 3: 8896.
  • 13
    Moreb JS, Maccow C, Schweder M et al. Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 2000; 293: 390396.
  • 14
    Bhatia M, Bonnet D, Murdoch B et al. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 1998; 4: 10381045.
  • 15
    Hess DA, Meyerrose TE, Wirthlin L et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 16481655.
  • 16
    Goodell MA, Rosenzweig M, Kim H et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 13371345.
  • 17
    Hess DA, Meyerrose TE, Wirthlin L et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated based on aldehyde dehydrogenase activity. Blood 2004; 104: 16481655.
  • 18
    Gallacher L, Murdoch B, Wu DM et al. Isolation and characterization of human CD34Lin and CD34+Lin hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 2000; 95: 28132820.
  • 19
    Storms RW, Goodell MA, Fisher A et al. Hoechst dye efflux reveals a novel CD7+CD34 lymphoid progenitor in human umbilical cord blood. Blood 2000; 96: 21252133.
  • 20
    Guan Y, Ralph S, Hogge DE. Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Exp Hematol 2002; 30: 721728.
  • 21
    Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a sub-population of cytogenetically normal CD34+CD38 progenitor cells from patients with acute myeloid leukemia. Blood 2001; 97: 38823889.
  • 22
    Wulf GG, Wang RY, Kuehnle I et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 11661173.
  • 23
    Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 42984302.
  • 24
    Tallman MS. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. Leukemia 1996; 10 (suppl 1):S12S15.
  • 25
    Russo J, Barnes A, Berger K et al. 4-(N, N-dipropylamino) benzaldehy de inhibits the oxidation of all-trans retinal to all-trans retinoic acid by ALDH1A1, but not the differentiation of HL-60 promyelocytic leukemia cells exposed to all-trans retinal. BMC Pharmacol 2002; 2: 4.